Literature DB >> 9572120

Report of the NIH Panel to Define Principles of Therapy of HIV Infection.

.   

Abstract

Recent research advances have afforded substantially improved understanding of the biology of human immunodeficiency virus (HIV) infection and the pathogenesis of the acquired immunodeficiency syndrome (AIDS). With the advent of sensitive tools for monitoring HIV replication in infected persons, the risk of disease progression and death can be assessed accurately and the efficacy of anti-HIV therapies can be determined directly. Furthermore, when used appropriately, combinations of newly available, potent antiviral therapies can effect prolonged suppression of detectable levels of HIV replication and circumvent the inherent tendency of HIV to generate drug-resistant viral variants. However, as antiretroviral therapy for HIV infection has become increasingly effective, it has also become increasingly complex. Familiarity with recent research advances is needed to ensure that newly available therapies are used in ways that most effectively improve the health and prolong the lives of HIV-infected persons. To enable practitioners and HIV-infected persons to best use rapidly accumulating new information about HIV disease pathogenesis and treatment, the Office of AIDS Research of the National Institutes of Health sponsored the NIH Panel to Define Principles of Therapy of HIV Infection. This Panel was asked to define essential scientific principles that should be used to guide the most effective use of antiretroviral therapies and viral load testing in clinical practice. Based on detailed consideration of the most current data, the Panel delineated eleven principles that address issues of fundamental importance for the treatment of HIV infection. These principles provide the scientific basis for the specific treatment recommendations made by the Panel on Clinical Practices for the Treatment of HIV Infection sponsored by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation. The reports of both of these panels are provided in this publication. Together, they summarize new dta and provide both the scientific basis and specific guidelines for the treatment of HIV-infected persons. This information will be of interest to health-care providers, HIV-infected persons, HIV/AIDS educators, public health educators, public health authorities, and all organizations that fund medical care of HIV-infected persons.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9572120

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  5 in total

1.  Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women.

Authors:  Tanya Telfair Sharpe; Lisa M Lee; Allyn K Nakashima; Laurie D Elam-Evans; Patricia L Fleming
Journal:  J Community Health       Date:  2004-04

2.  Effects of HIV Medication Complexity and Depression on Adherence to HIV Medication.

Authors:  Virender Kumar; William Encinosa
Journal:  Patient       Date:  2010-03-01       Impact factor: 3.883

Review 3.  Analytical and biological variables influencing quantitative hepatitis C virus (HCV) measurement in HIV-HCV coinfection.

Authors:  C L Cooper; Curtis L Cooper; Paul MacPherson; William Cameron
Journal:  Can J Gastroenterol       Date:  2006-01       Impact factor: 3.522

4.  Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment.

Authors:  M Holodniy; L Rainen; S Herman; B Yen-Lieberman
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

5.  Cost-effectiveness of HIV screening in patients older than 55 years of age.

Authors:  Gillian D Sanders; Ahmed M Bayoumi; Mark Holodniy; Douglas K Owens
Journal:  Ann Intern Med       Date:  2008-06-17       Impact factor: 25.391

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.